Folfiri is named as an intervention in 22 current clinical trials in our China, USA, UK, Ireland and India registers. 15 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Incyte Corporation (2). The most-studied condition is Metastatic Colorectal Cancer.
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Metastatic Colorectal Cancer | 4 |
| Solid Tumors | 3 |
| Advanced Colorectal Cancer | 2 |
| Colorectal Cancer Metastatic | 2 |
| Colorectal Cancer | 2 |
| Untreated, Unresectable, or Metastatic Colorectal Cancer | 1 |
| Advanced Solid Tumors | 1 |
| Metastatic Solid Tumors | 1 |
| Left-sided Colorectal Cancer | 1 |
| Cancer | 1 |
| Ras-mutated Metastatic Colorectal Cancer | 1 |
| mCRC | 1 |
| MSS Metastatic Colorectal Cancer | 1 |
| Colorectal Neoplasms | 1 |
| Gastrointestinal Neoplasms | 1 |
| Unresectable Metastatic Colorectal Cancer | 1 |
| CRC | 1 |
| KRAS/NRAS Mutation | 1 |
| Microsatellite Stable (MSS) Colorectal Cancer (CRC) | 1 |
| Metastatic Colorectal Cancer (CRC) | 1 |
| Non-small Cell Lung Cancer | 1 |
| Histiocytic Neoplasm | 1 |
| Histiocytosis | 1 |
| BRAF Gene Mutation | 1 |
| Colorectal Cancer Liver Metastasis | 1 |
| Neuroendocrine Neoplasm | 1 |
| Non-Small Cell Lung Cancer | 1 |
| Colorectal Carcinoma | 1 |
| KRAS G12C Mutation | 1 |
| Lead sponsor | Trials |
|---|---|
| Incyte Corporation | 2 |
| Mirati Therapeutics Inc. | 1 |
| Amgen | 1 |
| Bristol-Myers Squibb | 1 |
| Hoffmann-La Roche | 1 |
| Genmab | 1 |
| Tizona Therapeutics, Inc | 1 |
| Oncolytics Biotech | 1 |
| Janssen Research & Development, LLC | 1 |
| Celyad Oncology SA | 1 |
| Cardiff Oncology | 1 |
| Sun Yat-sen University | 1 |
| Shanghai Pudong Hospital | 1 |
| Haisco Pharmaceutical Group Co., Ltd. | 1 |
| Institut de Recherches Internationales Servier | 1 |
+ 6 more sponsors in the trial list above.
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 14 | 9 |
| Clinical trials in USA | 12 | 9 |
| Clinical trials in UK | 5 | 4 |
| Clinical trials in Ireland | 1 | 0 |
| Clinical trials in India | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
22 current trials in our China, USA, UK, Ireland and India registers name Folfiri as a drug or biological intervention, as of the registry sync on 25 September 2026. Completed and withdrawn studies are not counted.
Yes. 15 of the 22 trials are recruiting: 9 with sites in China, 9 with sites in USA, 4 with sites in UK and 1 with sites in India. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Incyte Corporation (2), Mirati Therapeutics Inc (1), Amgen (1) and Bristol-Myers Squibb (1), among 21 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Folfiri works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records โ it is not written from memory, and nothing here describes how Folfiri works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Folfiri (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 25 Sep 2026.